Lifeboat Foundation

Circa 2012

Hundreds of the world’s brightest minds — engineers from Google and IBM, hedge funds quants, and Defense Department contractors building artificial intelligence — were gathered in rapt attention inside the auditorium of the San Francisco Masonic Temple atop Nob Hill. It was the first day of the seventh annual Singularity Summit, and Julia Galef, the President of the Center for Applied Rationality, was speaking onstage. On the screen behind her, Galef projected a giant image from the film Blade Runner: the replicant Roy, naked, his face stained with blood, cradling a white dove in his arms.

At this point in the movie, Roy is reaching the end of his short, pre-programmed life, “The poignancy of his death scene comes from the contrast between that bitter truth and the fact that he still feels his life has meaning, and for lack of a better word, he has a soul,” said Galef. “To me this is the situation we as humans have found ourselves in over the last century. Turns out we are survival machines created by ancient replicators, DNA, to produce as many copies of them as possible. This is the bitter pill that science has offered us in response to our questions about where we came from and what it all means.”

Continue reading “Rapture of the nerds: will the Singularity turn us into gods or end the human race?” »

Click on photo to start video.

A follow on study from their previous human trial targeting IPF. This time the researchers ran a study to see how senolytics influenced diabetic kidney disease and if it actually removes senescent cells in humans.

Senescent cells, which can release factors that cause inflammation and dysfunction, the senescence-associated secretory phenotype (SASP), accumulate with ageing and at etiological sites in multiple chronic diseases. Senolytics, including the combination of Dasatinib and Quercetin (D + Q), selectively eliminate senescent cells by transiently disabling pro-survival networks that defend them against their own apoptotic environment. In the first clinical trial of senolytics, D + Q improved physical function in patients with idiopathic pulmonary fibrosis (IPF), a fatal senescence-associated disease, but to date, no peer-reviewed study has directly demonstrated that senolytics decrease senescent cells in humans.

Continue reading “For the September Journal Club we are taking a look at the new human trial data from the recent senolytics trial at the Mayo Clinic” »

Cell motility, the spontaneous movement of cells from one location to another, plays a fundamental role in many biological processes, including immune responses and metastasis. Recent physics studies have gathered new evidence suggesting that mammalian cells do not only crawl on solid substrates, including complex 3D mediums of a tissues, but can also swim in fluids.

In a recent study, a team of researchers at the University Grenoble Alpes and CNRS (National Center of Scientific Research) tried to shed light on the mechanisms behind the onset of motility cells in suspension, which would occur if they were moving in fluids. Their paper, published in Physical Review Letters, presents a model that couples actin and myosin kinetics with fluid flow, which they applied to a spherical and a non-spherical shape.

“Recent studies have suggested that adhesion is not necessary for cells to move in a three-dimensional environment, and have even shown that cells of the immune system can swim when suspended in a fluid,” the researchers who conducted the study told Phys.org via email.

Researchers from the U.S., Russia, and China have bent the rules of classical chemistry and synthesized a “forbidden” compound of cerium and hydrogen—CeH₉—which exhibits superconductivity at a relatively low pressure of 1 million atmospheres. The paper came out in Nature Communications.

Superconductors are materials capable of conducting an electric current with no resistance whatsoever. They are behind the powerful electromagnets in particle accelerators, maglev trains, MRI scanners, and could theoretically enable power lines that deliver electricity from A to B without losing the precious kilowatts to thermal dissipation.

Unfortunately, the superconductors known today can only work at very low temperatures (below −138 degrees Celsius), and latest record (−13 degrees Celsius) requires extremely high pressures of nearly 2 million atmospheres. This limits the scope of their possible applications and makes the available superconducting technologies expensive, since maintaining their fairly extreme operating conditions is challenging.

A breast cancer drug has been used to double the survival of men with advanced prostate cancer, becoming the first successful precision medicine for the disease.

Doctors at the Royal Marsden Hospital who conducted the trial say the results amount to a “revolution” in prostate cancer care.

They conducted genetic testing on more than 4,400 patients to identify those with one or more of 15 types of DNA fault.

Japanese researchers said they have developed artificial blood that can be transfused into patients regardless of their blood type and can vastly improve the chances for survival of seriously injured people.

The artificial blood created by a team of scientists primarily from the National Defense Medical College has proved effective in experiments on rabbits.

For possible applications on humans, the artificial blood gets around problems with identifying blood types in emergency situations and overcomes limits on storing real blood from donors.

Legendary inventor Dean Kamen is working on a venture to manufacture human organs with the backing of the Pentagon, Rockwell and others.

It’s not as morbid as you think; having a reliable way of predicting people’s mortality, especially as they age, could help to improve how doctors treat disease.

At our 2019 Ending Age-related Diseases conference in New York City, we had the pleasure of speaking with Dr. Michael West, the CEO of AgeX Therapeutics.

Dr. West can rightfully be called a pioneer in his field with a substantial background in biomedical and biotechnology corporations. After completing his PhD at Baylor College of Medicine, he founded Geron Corporation in 1990, where he launched and directed programs in telomere biology as it relates to cancer, aging, and human embryonic stem cell technology. He subsequently established the research group that went on to isolate human embryonic stem cells for the first time.

Continue reading “An Interview with Dr. Michael West” »